Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

-- Quarter Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch --

EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2008.

Key events since September 30, 2008 include:

Operational:

  • Closed on acquisition of Lev Pharmaceuticals, Inc. (Lev) in October 2008;
  • Initiated commercial launch of Cinryze for routine prophylaxis of hereditary angioedema (HAE);
  • Developed and successfully launched Cinryze patient access program, CinryzeSolutions(TM);
  • Launched new sales team in December for Cinryze;
  • Achieved net Vancocin(R) sales of $50 million during fourth quarter 2008; and
  • Increased research and development expenses by 70 percent over the fourth quarter of 2007, primarily driven by maribavir and Cinryze.

Development:

  • Filed supplemental Biologics License Application (sBLA) for Cinryze for treatment of acute attacks of HAE;
  • Granted priority review by the U.S. Food and Drug Administration for Cinryze sBLA for treatment of acute attacks of HAE, with a Prescription Drug User Fee Act (PDUFA) date of June 3, 2009; and
  • Discontinued maribavir clinical development program for prophylaxis against cytomegalovirus disease in transplant patients based on the preliminary analysis of phase 3 data.

Financial Results:

  • Achieved 16th consecutive quarter of positive cash flows from operations; and
  • Ended 2008 with working capital of $305 million, which includes cash, cash equivalents and short-term investments of $276 mi
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Greifensee, Switzerland (PRWEB) October 01, 2014 ... influence the quality of the final product. However, ... most regulated, regulatory frameworks such as Good Manufacturing ... is the responsibility of the manufacturer to interpret ... ensure consistent weighing performance quality. METTLER TOLEDO experts ...
(Date:10/1/2014)... Today the National Institutes of ... for the Brain Research through Advancing Innovative Neurotechnologies ... and revolutionize new methods of understanding the complexities ... This first round of grants totaling $46 million ... to more than 100 investigators in 15 states ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
Breaking Biology Technology:Comply with Weighing-Related Regulations in Pharma Manufacturing 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2
... 2011 Reaction Biology Corporation ("RBC"), a leading ... epigenetics, today announced the rollout of a new ... initial offerings will emphasize the histone methyltransferases (HMTs), ... no previous commercial source. The ...
... Fla., Oct. 24, 2011 GeneLink BioSciences, Inc. ... leading consumer genomics biotech company, today announced that it ... Deloitte,s ranking of 500 of the fastest growing technology, ... North America. GeneLink grew 4,363 percent during the period ...
... Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), ... People,s Republic of China, today announced that it has ... "200 Best Under a Billion" for the year 2011. ... for the year 2009. According to Forbes ...
Cached Biology Technology:Reaction Biology Launches Recombinant Methyltransferase Line 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... research, involving mice and published in the October 2014 ... , suggests that just because you can do ... team of Italian scientists have found that using marijuana ... immune system. This damage may result in autoimmune diseases ... bowel disease and rheumatoid arthritis in adulthood. , "I ...
(Date:9/30/2014)... with IVF? Here,s some hope: A new research report ... FASEB Journal , explains how scientists developed a ... which induced embryo development in human and mouse eggs ... the sperm cell during fertilization. , "We believe that ... shift in our understanding of human fertilization by providing ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... viruses is also involved in keeping cancer cells alive, researchers ... anti-viral molecule, called TBK-1, was found to be essential for ... a treatment for fighting cancer, the researchers report in today's ... that this mechanism is involved in cancer cell survival, even ...
... to transform into a new life, or into new cells ... in the mechanics - in how a single cell can ... this week in the Proceedings of the National Academy ... human egg. The identification opens the way to understanding these ...
... of different types of nerve cells by neural stem ... much of one kind of cell and too little ... brain malformations. In the October 6 issue of Cell, ... report discovering a new molecular pathway that influences the ...
Cached Biology News:Natural anti-viral enzyme helps keep cancer cells alive, researchers find 2Scientists crack genetic secrets of human egg 2Novel pathway regulates timing of brain cell development 2
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
PPIF Antibody...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: